What did @myriamestrella8 actually say?
The creator, who says she's been on a GLP-1 medication for a year and a half and lost nearly 100 pounds, ran through five side effects she claims "nobody talks about": sulfur burps, fatigue from undereating, constipation, reduced joint pain, and what she calls "food grief." She also endorsed Mochi Health as cheap, fast-shipping, and doctor-supervised.
To be clear about what she's actually claiming: sulfur burps are real and unpleasant, fatigue can result from not eating enough, constipation is a documented complaint, joint pain improved for her, and the emotional relationship with food changed in ways that required actual psychological work. That's a more honest set of claims than most GLP-1 content on TikTok, though one of them needs a closer look.
Does the science back this up?
Mostly, yes, with one significant exception. Three of the five side effects she names are well-documented in clinical literature. The fourth is more complicated than she presents it.
Sulfur burps and gastrointestinal complaints are among the most commonly reported adverse effects of semaglutide and tirzepatide. A 2021 NEJM trial by Wilding et al. on semaglutide 2.4mg found that roughly 44% of participants reported nausea and other GI symptoms. Constipation specifically appeared in around 24% of participants in that same trial. Her advice to eat more fiber is also reasonable, consistent with standard dietary guidance for managing GLP-1-related constipation.
Fatigue from caloric restriction is real, though it's worth noting that fatigue is also a direct reported side effect in trials, not just a downstream consequence of eating less. The distinction matters clinically.
The joint pain claim is where things get genuinely interesting and require more nuance than she gave it.
What did they get wrong (or right)?
Her claim about joint pain deserves the most scrutiny. She says "nobody told me I wouldn't have like aches and pains" and attributes the relief to being on a GLP-1 for a year and a half. That framing conflates two separate mechanisms, and she doesn't distinguish between them.
Yes, GLP-1 receptor agonists have shown anti-inflammatory properties in research settings. A 2023 analysis by Falkenberg et al. in Frontiers in Immunology reviewed evidence suggesting GLP-1 receptors modulate inflammatory pathways. But in a person who has also lost nearly 100 pounds, reduced joint load is a much simpler and more established explanation for less knee pain. Attributing joint relief directly to the drug's anti-inflammatory action, without acknowledging weight loss as the more obvious variable, overstates what we currently know.
What she got right is the "food grief" framing. This is a real and underreported psychological dimension of GLP-1 use. Researchers including Chao et al. (2023, Obesity) have documented that reduced food reward responses can create emotional disruption in patients who used food as a coping mechanism. She's describing something clinically meaningful, and she's being honest that it required psychological work to manage. That's a more responsible take than most content in this category.
What should you actually know?
A few things this video doesn't cover that matter if you're considering a GLP-1 medication.
- Sulfur burps are often tied to delayed gastric emptying, which is a known mechanism of GLP-1 drugs. They tend to improve as your body adjusts to the medication, particularly when doses are titrated slowly.
- Constipation on GLP-1s is not just about fiber. Adequate hydration and, in some cases, osmotic laxatives are recommended. Talk to a clinician before self-managing.
- The "food grief" she describes has a clinical name in some literature: hedonic dysregulation. It's not universally negative, but patients with pre-existing disordered eating histories should discuss this with a mental health provider before starting treatment.
- Her claim that Mochi Health is "literally the cheapest around" is a marketing claim, not a clinical one. Compounded GLP-1 medications from telehealth platforms are not equivalent to FDA-approved branded formulations. Pricing and quality control vary. That distinction matters for safety and efficacy.
- She disclosed this is a paid partnership (#mochipartner). That doesn't make her experience false, but it's context you need when evaluating her platform recommendation.
Her personal experience appears genuine. Her medical framing is mostly reasonable. But this is one person's anecdote, not a clinical guide, and the joint pain claim specifically deserves more skepticism than she applied to it.